These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 36257911

  • 1. An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma.
    Tella SH, Mahipal A.
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [Abstract] [Full Text] [Related]

  • 2. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
    Corrigan L, Lowery M.
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
    [Abstract] [Full Text] [Related]

  • 3. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
    Roth GS, Neuzillet C, Sarabi M, Edeline J, Malka D, Lièvre A.
    Eur J Cancer; 2023 Jan; 179():1-14. PubMed ID: 36463640
    [Abstract] [Full Text] [Related]

  • 4. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
    Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK.
    JAMA Oncol; 2021 Nov 01; 7(11):1669-1677. PubMed ID: 34554208
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
    Kehmann L, Berres ML, Gonzalez-Carmona M, Modest DP, Mohr R, Wree A, Venerito M, Strassburg C, Keitel V, Trautwein C, Luedde T, Roderburg C.
    BMC Cancer; 2023 May 22; 23(1):470. PubMed ID: 37217885
    [Abstract] [Full Text] [Related]

  • 8. [Not Available].
    Valéry M, Cervantes B, Smolenschi C, Boige V, Ducreux M, Cohen R, Hollebecque A.
    Bull Cancer; 2022 Nov 22; 109(11S):11S21-11S27. PubMed ID: 36535759
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
    Rabehi T, Quesada S.
    Bull Cancer; 2023 Dec 22; 110(12):1230-1231. PubMed ID: 37704495
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ivosidenib Boosts OS in Cholangiocarcinoma.
    Cancer Discov; 2021 Dec 01; 11(12):2953-2954. PubMed ID: 34635569
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L.
    Target Oncol; 2022 Sep 01; 17(5):517-527. PubMed ID: 36114955
    [Abstract] [Full Text] [Related]

  • 15. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
    Casak SJ, Pradhan S, Fashoyin-Aje LA, Ren Y, Shen YL, Xu Y, Chow ECY, Xiong Y, Zirklelbach JF, Liu J, Charlab R, Pierce WF, Fesenko N, Beaver JA, Pazdur R, Kluetz PG, Lemery SJ.
    Clin Cancer Res; 2022 Jul 01; 28(13):2733-2737. PubMed ID: 35259259
    [Abstract] [Full Text] [Related]

  • 16. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    Merters J, Lamarca A.
    J Hepatol; 2023 Mar 01; 78(3):652-657. PubMed ID: 36400328
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Biliary cancer: gateway to comprehensive molecular profiling.
    Sardar M, Shroff RT.
    Clin Adv Hematol Oncol; 2021 Jan 01; 19(1):27-34. PubMed ID: 33493146
    [Abstract] [Full Text] [Related]

  • 19. Ivosidenib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE.
    Target Oncol; 2023 Nov 01; 18(6):973-980. PubMed ID: 37855990
    [Abstract] [Full Text] [Related]

  • 20. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
    Ricci AD, D'Alessandro R, Rizzo A, Schirizzi A, Vallarelli S, Ostuni C, Troiani L, Lolli IR, Lotesoriere C, Giannelli G.
    Immunotherapy; 2023 May 01; 15(7):477-486. PubMed ID: 36950960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.